C
ancers are collectively the leading causes of premature death in the United States and their incidence is increasing as the population ages. 1 Breast cancer is the most common of the cancer diagnoses and the second leading cause of cancer death in women in both the US and in the state of Georgia. 2, 3 Ovarian cancer is the ffth leading cause of cancer death and is often diagnosed at more advanced stages. Although multiple factors have been associated with an increased risk of breast and ovarian cancer, family history remains the most signifcant and consistent predictor of cancer risk. 4, 5 Systematic collection of family history, referral of high-risk women to cancer genetic services, and selective genetic testing can identify a mutation in a hereditary cancer gene. When followed by cascade Background The Georgia Breast Cancer Genomics Project identifed minority and underserved women at high risk for hereditary breast and ovarian cancer based on family history. Education, web-based screening, genetic counseling, and testing were provided in public health and primary care settings in accordance with evidence-based recommendations and guidelines. Objectives To assess risk of hereditary breast and ovarian cancer (HBOC) among minority and underserved women, provide genetic services according to evidence-based guidelines, and evaluate provider knowledge of HBOC. Methods The Georgia Department of Public Health established this project through a cooperative agreement with the Centers for Disease Control and Prevention. HBOC screening and genetic services were provided in 13 public health centers and federally qualifed health centers. Staff received training on genetics and risk assessment using the Breast Cancer Genetics Referral Screening Tool (B-RST). Providers and medical residents were surveyed on their knowledge of HBOC. Young women with breast cancer were surveyed on receipt of genetic services. Results More than 5,400 women were successfully screened; 79% identifed as racial/ethnic minorities. 5% of women screened positive on the B-RST, which is consistent with HBOC prevalence; 79% agreed to follow up. 23% met criteria for increased risk of BRCA 1/2 mutation and received genetic counseling and testing. Surveys revealed profound gaps in knowledge among physicians and medical residents and lack of delivery of evidence-based genetic services to survivors. Conclusions The genomics project demonstrated the effcacy of population-based screening to identify high-risk women before they receive a diagnosis of cancer. A high percentage of women who screened positive also completed genetic counseling and testing. Access to the benefts of HBOC management to prevent cancer and decrease mortality among minority and underserved women depends on improvements in knowledge of genetics and evidence-based practice by providers. Although hereditary breast and ovarian cancer (HBOC) syndrome associated with mutations in the BRCA 1/2 genes is not common in the general population, women who carry mutations in those genes face a substantially higher risk of breast and ovarian cancer than the general population. Data from the National Cancer Institute (NCI) have revealed that between 1 in 400 and 1 in 800 women in the general population have a BRCA 1/2 mutation. 7 About 1 in 40 women of Ashkenazi Jewish descent carry a founder BRCA 1/2 mutation. 7 Te average population lifetime risk for breast cancer is 1:8 (13%) and for ovarian cancer, 1:70 (1.5%); lifetime risks for breast and ovarian cancer in BRCA 1/2 mutation carriers range from 40%-80% and from 10%-40%, respectively. 8 Ofering genetic counseling and testing for BRCA 1/2 to women who are at increased risk for HBOC can guide targeted cancer surveillance, prevention strategies, and infuence lifestyle decisions that reduce cancer-related morbidity and mortality. 7 For women who test positive for a BRCA 1/2 mutation, interventions that include chemoprevention, enhanced surveillance, or prophylactic mastectomy and salpingo-oophorectomy can decrease the incidence of breast and ovarian cancer by up to 95% and 80%, respectively. [9] [10] [11] [12] [13] Despite these clear benefts, the literature demonstrates under-referral to and under-use of genetic counseling and testing, particularly for minority and underserved women. Racial/ethnic minorities include African Americans, Hispanics, and Asians. Tere were no Native Americans to report. Underserved is defned as those seeking care in free or reduced-cost public health centers and federally qualifed health centers. 14, 15 Te Precision Medicine Initiative launched by President Obama in January 2015 is accelerating research on the methods by which we prevent, diagnose, and treat cancers, and has emphasized the potential impact of analyzing inherited genetic variations. 16 Concurrently, changes in federal law have resulted in the wider incorporation of population health improvement concepts into public health practice and patient-centered medical homes. Population health improvement relies on the provision of evidence-based, multidisciplinary care that emphasizes care coordination, integration of screening into practice, and addressing health disparities to prevent illness and provide better quality care. 17 Evidence-based guidelines of the US Preventive Services Task Force (USPSTF), the National Comprehensive Cancer Network (NCCN) and the American College of Surgeons' Commission on Cancer (CoC) indicate that women with a personal or family history of breast and/or ovarian cancer may beneft from genetic counseling and testing. Family history indicators associated with increased likelihood of potentially harmful BRCA 1/2 mutations include a known BRCA 1/2 mutation in the family; breast cancer diagnosis before age 50; ovarian cancer at any age; bilateral breast cancer; triple-negative breast cancer; presence of breast and ovarian cancer in the same individual; presence of breast cancer in male family members; multiple cases of breast cancer in the family; 1 or more family members with 2 primary types of BRCA 1/2-related cancer; and Ashkenazi Jewish ancestry. [18] [19] [20] Use of genetic services and extension of the benefts of genetic research to minority and underserved women is a specifc objective of Healthy People 2020, an initiative by the Ofce of Disease Prevention and Health Promotion, though it is still in its infancy. Minority and underserved women face substantial obstacles that limit the benefts of cancer genetic risk assessment, testing, and cancer risk management. Tese women may lack information regarding the impact of family history on cancer risk; have limited geographic and fnancial access to cancer risk assessment; and receive fewer referrals for appropriate services. 21, 22 Increasing the proportion of minority and underserved women with a family history of breast and/or ovarian cancer who receive genetic counseling and testing should reduce cancer disparities, enhance cancer and noncancer health outcomes, and ensure that these women are receiving evidence-based, high-quality care.
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Georgia Breast Cancer Genomics project Te cancer burden experienced by Georgians is complicated by geographic barriers, socioeconomic status, and access to care. Georgia's population is 10.2 million and its land mass makes it the largest state east of the Mississippi river. Twenty-fve percent of the population is rural; 19% lives below the poverty level, and 18% is uninsured. Racial and ethnic minorities comprise 45% of the population, including 32% African Americans, 9% Hispanics, and 4% Asians. 8, 3 Te early identifcation of minority and underserved women with BRCA 1/2 mutations requires integration of education, risk assessment, and genetic services into settings where these women seek health care. To be most efective, health care providers must engender the trust of women in their care. 14, 15, 23 Te Georgia Breast Cancer Genomics project was designed to address disparities in access to care in patients in Georgia who are at risk for hereditary cancer. Te spe- Te genomics project used population health improvement strategies to identify minority and underserved women who were at high risk for HBOC through the following activities: n Educating public health professionals and primary care providers (PCPs) on cancer genetics and methods to identify women at increased risk for HBOC using a multidisciplinary genomics curriculum; n Implementing validated web-based screening for women at risk for HBOC in settings serving minority and underserved women, including public health centers and federally qualifed health centers; n Delivering HBOC education, risk assessment, and resources to minority and underserved women in community-based public health and primary care settings; n Providing genetic counseling and comprehensive cancer risk assessment to women identifed as at-risk for HBOC by screening; n Facilitating genetic testing for those meeting NCCN and other guidelines.
Method
In the frst 3 years of operation, the genomics project integrated screening for women at risk for HBOC, as well as provision of genetic services, into 13 community-based public health and primary care settings in which free and reduced cost care was provided. No additional clinic staf was required to implement the program: members of the project provided administrative, educational, and clinical support. Potential fnancial barriers to access to the support were eliminated by providing genetic counseling and testing free of charge through a combination of grant funding and industry support. Screening for women at risk for HBOC was conducted by staf trained by multidisciplinary members of the genomics project to implement the Breast Cancer Genetics Referral Screening Tool (B-RST). Te B-RST is a validated screening tool designed to identify women who should be referred for cancer genetic services for HBOC. Te tool is available at www.BreastCancerGeneScreen.org in English and Spanish. [26] [27] [28] In 2013, B-RST was recommended by the USPSTF as a simple, quick, and clinically useful tool to help identify women who might beneft from a genetic counseling referral. Te screening tool is comprised of 6 questions, takes less than 5 minutes to complete, and uses select family history information to identify women at risk for HBOC. 20 Based on a clinical algorithm, the tool provides 3 possible results related to the risk of developing HBOC: negative-low risk, negative-moderate risk, or positive-high risk. HIPAA-compliant electronic data capture was integrated into a secured database located on the www.BreastCancerGeneScreen.org website to facilitate the collection of patient demographic data, track risk assessment results, and disseminate HBOC-related information and resources. Women with positive-high risk screening results were ofered formal genetic counseling services, including detailed family history documentation and cancer risk assessment by a qualifed genetics professional in person or by telephone.
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Results
More than 5,400 women were successfully screened using the B-RST during 2011-2014. In all, 4,293 (79%) of those women self-identifed as racial or ethnic minorities. Women who screened positive/high risk on the B-RST represented 5% (287) of the total number screened, which aligns with the HBOC prevalence rate across the country. Of the 227 (79%) women who screened positive and agreed to follow-up, 173 (67%) were successfully contacted. During a genetic counseling session, a detailed family history was collected, and 40 women (23%) met criteria for an increased risk for a BRCA 1/2 mutation. Tese women underwent in-depth genetic counseling and all chose to proceed with genetic testing. Among the 40 women who were tested for BRCA 1/2, 1 pathogenic mutation and 4 variants of uncertain signifcance were identifed. All of the women received education and risk-appropriate guidance for screening and healthy lifestyle behaviors. Nine women were diagnosed with breast cancer following a positive/ high risk B-RST screening; none of them were found to have a BRCA 1/2 mutation, though all had a suggestive family history.
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Surveys of PCPs, medical residents, and breast cancer survivors Pilot surveys of primary care providers, medical residents, and young breast cancer survivors were designed and conducted by the genomics project staf to inform development and implementation of HBOC education, risk assessment, and genetic services. Two of the surveys assessed clinician knowledge of HBOC genetics -the Original Report frst among PCPs, and the second among primary care resident physicians in training. Accurate understanding of genetics and HBOC among clinicians is essential to provision of evidence-based care including the appropriate referral of at-risk patients to genetic services. Tis knowledge is also critical for the future of precision medicine. A third survey was designed to assess the use of genetic services and testing among young breast cancer survivors (diagnosed under age 50 years) who met NCCN guidelines for further genetic risk evaluation.
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Knowledge of HBOC syndrome among Georgia PCPs (2012)
A 34-question survey was developed to assess basic knowledge of HBOC and application of genetic principles among primary care providers. 30 One thousand surveys were mailed to randomly selected licensed health care providers (family practice, internal medicine, midlevel provider, and obstetrics and gynecology) in Georgia, with a $5 cash incentive and postage-paid envelope. Surveys were completed by 369 (37%) respondents with 275 (75%) of those eligible for analysis. Among the providers, about 35% rated themselves as highly confdent in their knowledge of HBOC. Tey demonstrated some knowledge of basic genetic principles, but were unable to consistently identify individuals at greatest risk for HBOC. Knowledge defcits included limited understanding of inheritance patterns and failure to recognize the risk impact of ovarian cancer (96%) or a known BRCA1/2 mutation in the family (74%). A summary of these results is shown in Table 1 , which includes analysis of the percentage of correct answers by specialty. Ob-gyns consistently scored higher than the other specialties, though this diference was signifcant only for the questions regarding inheritance pattern and risk given a familial mutation. Of note is the fnding that only 3.9% of respondents identifed a woman with ovarian cancer and a family history of ovarian cancer as high risk.
Te results of the surveys support further educational eforts with a specialty and case-based approach directed toward primary health care providers as critical to ensuring that patients at greatest risk for HBOC are identifed and referred for genetic counseling.
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HBOC education needs of Georgia primary care residency training programs (2014) Surveys were distributed electronically to 22 primary care medical residency training programs in Georgia, including family medicine, obstetrics and gynecology, and internal medicine specialties, and responses were received from 10 facilities (45% response rate). Program directors or faculty representatives were asked to complete a survey on HBOC education within their curricula. Residents currently enrolled in the medical residency programs (n = 122) were asked to complete a knowledge survey of key HBOC concepts. Fifty-seven percent of respondents did not recall having received education regarding HBOC; 51% were not able to identify autosomal dominant inheritance; and 31% failed to recognize that a BRCA1/2 mutation can be maternally or paternally inherited. Self-rated confdence levels of residents were largely in the average range as presented in the Figure. Residency curricula content is presented in Table 2 .
Te results of the survey suggest that targeted educational intervention during residency training may be necessary to improve the ability of PCPs to accurately identify and appropriately refer families at increased risk for HBOC in order to maximize the benefts of available genetic services and cancer prevention strategies.
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Receipt of genetic services among young breast cancer survivors (2014)
A 47-item anonymous survey was completed electronically by 292 young breast cancer survivors (diagnosed at younger than 50 years) through the Georgia-based breast cancer survivor support group listserv. Questions focused on referral for and receipt of cancer genetic services, with additional questions related to genetic services barriers, facilitators, and motivators. Forty-nine percent of respondents reported receiving a referral or recommendation for genetic counseling, with 37% actually receiving those services and 16.5% undergoing genetic testing. Twenty-seven percent reported insurance coverage as the main barrier to seeking genetic services (lack of coverage or high outof-pocket cost). Only 20% of those who were having testing reported they did so because they understood it was important to their care. Of the respondents, 181 (62%) identifed themselves as racial or ethnic minorities. Tese data suggest that young breast cancer survivors in Georgia are unlikely to receive genetic services in accordance with NCCN guidelines and highlight the need to incorporate genetic education and referral into routine clinical care for this group of breast cancer patients. In addition, education of young breast cancer patients will empower them to request genetic services. Policy makers should also consider innovative ways to improve referral to, uptake and receipt of cancer genetic services among young breast cancer survivors.
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Summary and conclusions
Te genomics project identifed minority and underserved women at high risk for HBOC (based on family history) who would not otherwise have had access to genetic/ genomic services, and it provided education, counseling, and testing in accordance with the evidence-based recommendations and guidelines. Population-based screening is recommended based on the marked increase in the lifetime risk of breast and ovarian cancer for BRCA 1/2 mutation carriers. Tus far, in Georgia, more than 5,400 minority and underserved women have undergone screening for HBOC as part of the genomics project. Although 1 woman was identifed as having a pathogenic mutation and 4 were identifed has having variants of uncertain signifcance, these numbers are consistent with national prevalence of HBOC. Te project's impact through genetics education of providers and increased information and awareness among women is signifcant and is critical in light of the increased cancer burden, late stage of diagnosis, and high mortality rates in this population. As concluded by Traxler and colleagues, the "expansion of this protocol may contribute to a long-term reduction in health inequity related to cancer incidence and mortality among high-risk and minority populations." 29 Te population health improvement strategy described in this project -integration of screening for individuals at risk for hereditary cancer into existing clinical practice -demonstrates how a simple, practical, low-resource intervention can address existing health disparities. Te introduction of web-based screening using the B-RST efciently and efectively facilitated risk assessment for HBOC. Financial barriers were minimized by providing genetic services, including genetic testing, at no cost to the women served. Te genomics project also demonstrated a method of incorporating cancer genetic risk assessment and services into public health centers and community-based health care settings that can be replicated and further expanded through telemedicine. A critical factor to consider in replicating this methodology is that screening for HBOC should be accompanied by education, and when appropriate, genetic counseling and testing. In addition, women who test positive for mutations should be referred to providers to discuss options to decrease future risks of cancer including chemoprevention, enhanced surveillance, and surgery.
Despite the positive results of the project, survey results revealed profound gaps in knowledge of genetics and HBOC among both PCPs and medical residents. Both groups indicated interest in educational opportunities, to enhance their knowledge of HBOC and appropriate referral practices for genetic services. Respondents' preferences Original Report included an interactive case-based approach with application to practice and self-guided web or journal programs with continuing education credit. Survey results also identifed defciencies in the receipt of genetic services among young women with breast cancer who are most likely to have HBOC. Access to the benefts of genetic services and HBOC management to prevent cancer and decrease mortality among minority and underserved women depends on improvements in knowledge of genetics and evidencebased practice by providers. Such improvement will also shape the future implementation of the national precision medicine initiative. Based on our fndings, we conclude that it is feasible to incorporate genetic risk assessment for HBOC into clinical practice even among diverse populations in underserved settings, and that the delivery of evidence-based care requires improved provider knowledge of genetics, HBOC, and recognition of the importance of genetic services. Identifcation of HBOC is merely one step toward reversing cancer disparities for minority and underserved women; they must also receive appropriate genetic services, clinical management, and continuing access to low-or nocost screenings through programs such as the Breast and Cervical Cancer Program of the Georgia Department of Public Health. Te genomics project highlighted the ability to provide such services in a large and diverse population. Until provider awareness of HBOC referral and management guidelines is consistent with current evidence, a model of intervention such as the genomics project may be essential to population-based HBOC risk assessment. Minority and underserved women are unlikely to receive the proven and recommended benefts of evidence-based care that could prevent future cancers and reduce cancer related mortality in the absence of enhanced provider knowledge of genetics and HBOC. Future work should thus focus on development of educational interventions customized to improve provider knowledge according to specialty, with the goal of increasing the number of women at risk for HBOC who are appropriately referred for cancer genetic services.
